XML 35 R4.htm IDEA: XBRL DOCUMENT v2.4.0.6
Consolidated Statements of Operations and Comprehensive Loss (unaudited) (USD $)
In Thousands, except Share data, unless otherwise specified
 3 Months Ended 9 Months Ended 129 Months Ended
Sep. 30, 2012
Sep. 30, 2011
Sep. 30, 2012
Sep. 30, 2011
Sep. 30, 2012
Costs and expenses:          
Research and development $ 156 $ 533 $ 901 $ 1,720 $ 42,486
Selling, general and administrative 772 1,288 2,579 4,007 41,935
Merger transaction costs             5,470
Restructuring expense, net             2,413
Loss on impairment of in-process research and development             6,000
Total costs and expenses 928 1,821 3,480 5,727 98,304
Loss from operations (928) (1,821) (3,480) (5,727) (98,304)
Gain on bargain purchase             25,282
Gain on assignment of patent rights          2,000 2,000
Interest and other income 2 1 3 2 2,029
Interest and other expense (1) (2) (3) (9) (442)
Loss before income taxes (927) (1,822) (3,480) (3,734) (69,435)
Benefit from income taxes             2,281
Net Loss and Comprehensive Loss (927) (1,822) (3,480) (3,734) (67,154)
Less: Accretion of redeemable convertible preferred stock             (245)
Less: Deemed preferred stock dividend for additional common shares issuable under anti-dilution provisions             (781)
Net Loss attributable to common stockholders $ (927) $ (1,822) $ (3,480) $ (3,734) $ (68,180)
Net loss attributable to common stockholders per share:          
Basic and Diluted $ (0.07) $ (0.17) $ (0.27) $ (0.38)  
Weighted average shares outstanding:          
Basic and Diluted 13,702,418 10,499,472 12,682,077 9,821,706